Navigation Links
Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse
Date:5/20/2013

Newport News, VA (PRWEB) May 20, 2013

Orthopaedic & Spine Center announced today that Dr. Jeffrey Carlson successfully performed a procedure using SpineFrontier’s FacetFuse Screw System in conjunction with their P-LIFT Lumbar Interbody Fusion Device System. The operation took place on Tuesday, April 16, 2013 at Bon Secours Mary Immaculate Hospital in Newport News, VA. The surgery was a facet joint fusion of the lumbar spine on a 66 year-old, female patient.

Dr. Carlson described the case, saying the patient “…had significant back pain and leg pain with neurologic compression. Multiple efforts at conservative treatment, including medications, injections and therapies were unable to give her any long-lasting improvement.” Dr. Carlson also commented on the FacetFuse technology used in the procedure, “I was very impressed with the FacetFuse screws with their integrated washer design. The screws themselves felt very secure in their insertion. The integrated washer design allows for excellent compression across the interbody space and across the facet joint. The significant torque that can be placed on the screws allows the surgeon to feel quite confident that these screws will provide a secure fixation.”

The FacetFuse Screw System is a transfacet pedicle screw system in which two screws replace four pedicle screws, rods and locking caps. The reduced amount of hardware is intended to decrease OR time. The FacetFuse system accommodates open, percutaneous, minimally invasive and less exposure surgery techniques, allowing for a single, small, midline incision that preserves tissues and leaves stabilizing muscles intact. Additionally, the low profile FacetFuse screw head preserves adjacent level anatomy that might otherwise be compromised when compared to pedicle screws. FacetFuse provides direct compression across the facet joint and disc space when the lag screw is inserted, thereby requiring no secondary mec
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Jeffrey W. Olin, DO, authors study that describes symptoms and severity of fibromuscular dysplasia
2. Dr. Jeffrey M. Kenkel Selected Among Top 1% of Plastic Surgeons by US News & World Report
3. CNIO scientists successfully test the first gene therapy against aging-associated decline
4. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
5. New drug successfully halts fibrosis in animal model of liver disease
6. Barrow researchers successfully destroy brain tumor cells
7. Muscular Contusions Are Now Being Treated Successfully by Dr. Farshchian Using Cell Therapy
8. Dr. Farshchian: Muscular Contusions are Now Being Treated Successfully at The Center for Regenerative Medicine in Miami
9. Tips For Weight Loss from Health Reviews - How the “Fat Loss Factor” Helps People Lose Weight Successfully
10. Eco Smart Energy, LLC Successfully Installs Eco-Friendly, Cost Saving Sun Equinox System at Dallas Stars’ Dr. Pepper StarCenter
11. Chinese Herbal Medicine Can Reach into Prostate Gland and Treat Prostatitis Successfully As A New Option for Prostatitis Sufferers, States Wuhan Dr.Li's Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Medic, the Mecklenburg EMS,Agency, has fully ... Center, which will offer the most-advanced and,challenging ... emergency,medical services personnel. Using interactive robotic ... scene and situation, trainees face evolving,scenarios controlled ...
... that it was easy to quit smoking because he did it ... why some people find it so difficult to stop smoking even ... statistics provided by the Centers for Disease Control and Prevention (CDC), ... United States, and it is the second major cause of death ...
... features include remote printing, real-time medical necessity checking, ... for draw-station future orders., MENLO PARK, Calif., ... applications for healthcare and integration software,solutions, today announced ... Blue Iris eLaborate provides a flexible, easy-to-use, web-based ...
... Synova Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today ... in aggregate notional principal amount of its,6.5% senior convertible ... common stock purchase warrants. This sale was effected as ... and warrants in the,aggregate notional principal amount of up ...
... NEW YORK Repeated courses of a drug that ... babies also may increase the risk of cerebral palsy ... study, funded by the National Institutes of Health and ... gynecology, Columbia University Medical Center and attending obstetrician and ...
... to female sex-change surgery are happy with the results, despite ... of over 200 patients in the September issue of the ... the Departments of Urology and Psychiatry at University Hospitals of ... patients who had undergone surgery and 70 who took part ...
Cached Medicine News:Health News:Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel 2Health News:Genetic variation affects smoking cessation treatment 2Health News:MITEM Releases Blue Iris eLaborate 8.6 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Repeat steroids to premature infants linked to cerebral palsy 2Health News:Most patients who have male-to-female sex-change surgery are happy, despite complications 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... WIRE via COMTEX News Network),-- Endo Pharmaceuticals ... Holdings Inc. (NASDAQ: ENDP), has presented results,from ... evaluating Frova (frovatriptan succinate) 2.5 mg,tablets as ... menstrual migraine (MM). The data demonstrated,that FROVA ...
... SALT LAKE CITY, UT, June 11, 2007 ... Genetics, Inc. (NASDAQ: MYGN) (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ... comparison of a,"Staggered Start" and a "Randomized ... Staggered Start" clinical trial,design at the Alzheimer's ...
Cached Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: